甘肃陇神戎发药业股份有限公司 独立董事 2024 年度述职报告 2024 年度，本人未在公司担任除独立董事外的其他职务，并与公司及控股 股东、实际控制人不存在直接或者间接利害关系，或者其他可能影响本人进行独 立客观判断的关系，符合《上市公司独立董事管理办法》以及《公司章程》《独 立董事制度》中关于独立董事独立性的相关规定。 二、2024 年度履职情况 （一）出席董事会及股东大会会议情况 2024 年度，公司共召开了 12 次董事会和 6 次股东大会，本人均按时出席相 关会议。作为独立董事，本人在审议提交董事会的相关事项时，与公司及相关方 保持密切沟通，提前审阅相关资料，客观、独立、审慎地行使表决权，对所审议 的各项议案均投了同意票。本人认为，公司 2024 年度董事会、股东大会的召集、 召开和表决符合法定程序，重大经营事项均履行了相关决策程序。 （罗臻） 本人作为甘肃陇神戎发药业股份有限公司（以下简称"公司"）的独立董事， 2024 年度严格按照《公司法》《证券法》《上市公司独立董事管理办法》《深 圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等 法律法规和《公司章程》《独立董事制度》 ...

一、主要会计数据和财务指标 | 报告期指标 | 2024年年报 | 2023年年报 | 本年比上年增减(%) | 2022年年报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 0.0851 | 0.2032 | -58.12 | 0.1279 | | 每股净资产（元） | 2.18 | 2.09 | 4.31 | 2.46 | | 每股公积金(元) | 0.28 | 0.22 | 27.27 | 0.76 | | 每股未分配利润(元) | 0.80 | 0.77 | 3.9 | 0.60 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 10.39 | 10.8 | -3.8 | 8 | | 净利润(亿元) | 0.26 | 0.62 | -58.06 | 0.39 | | 净资产收益率(%) | 4.02 | 7.17 | -43.93 | 3.52 | 前十大流通股东累计持有： 12073.8万股，累计占流通股比： 39.99%，较上期变化： -126.50万股。 | 名称 持有数量(万股) | | 占总股本比例 ...

Financial Performance - The company's operating revenue for 2024 was CNY 1,039,067,296.23, a decrease of 3.79% compared to CNY 1,080,050,028.71 in 2023[19]. - The net profit attributable to shareholders for 2024 was CNY 25,804,597.33, representing a significant decline of 58.14% from CNY 61,647,653.41 in 2023[19]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 49,127,153.30, down 4.93% from CNY 51,677,023.69 in 2023[19]. - The net cash flow from operating activities increased by 76.27% to CNY 170,144,339.46 in 2024, compared to CNY 96,526,292.90 in 2023[19]. - The total assets at the end of 2024 were CNY 1,402,312,065.83, an increase of 4.91% from CNY 1,336,651,461.91 at the end of 2023[19]. - The net assets attributable to shareholders increased by 4.51% to CNY 662,284,451.05 at the end of 2024, compared to CNY 633,705,992.72 at the end of 2023[19]. - Basic earnings per share for 2024 were CNY 0.0851, down 58.12% from CNY 0.2032 in 2023[19]. - The weighted average return on net assets for 2024 was 4.02%, a decrease of 3.16% from 7.18% in 2023[19]. Dividend Distribution - The company plans to distribute a cash dividend of CNY 0.20 per 10 shares to all shareholders, based on a total of 303,345,000 shares[5]. - The company plans to distribute cash dividends of RMB 0.20 per 10 shares, totaling RMB 6,066,900.00 for the fiscal year 2023[169]. - For the fiscal year 2024, the company will also distribute cash dividends of RMB 0.20 per 10 shares, totaling RMB 6,066,900.00[172]. - The cumulative undistributed profits as of December 31, 2024, amount to RMB 242,099,194.45 for the consolidated statements and RMB 207,437,816.86 for the parent company[172]. Industry Context - The overall performance of the pharmaceutical industry in 2024 is under pressure due to macroeconomic changes, drug price controls, and rising raw material costs, impacting profit margins[30]. - The total revenue for the pharmaceutical manufacturing industry in 2024 was ¥25,298.50 billion, remaining stable compared to 2023, while total profit decreased by 1.1% to ¥3,420.70 billion[30]. - The pharmaceutical industry is expected to experience growth due to increasing demand from an aging population and rising health awareness[101]. - Challenges include price pressures from centralized procurement and rising production costs due to commodity price increases[102]. Product Development and Innovation - The company has developed a fully automated capsule packaging production line, showcasing its innovation in smart manufacturing[37]. - The company is actively developing new products and enhancing its core products' market share through increased marketing efforts[47]. - The company is developing the "Longshen牌斗九片" health food product, aiming to obtain health food registration to enhance product variety and market competitiveness[81]. - The company is in the research phase for the "陇药名方" industrial processing project, targeting drug registration to improve product structure and competitiveness[81]. - The company is committed to advancing key technology research projects, including the registration and production of blood dialysis concentrates and the development of health products[108]. Regulatory Compliance and Governance - The company has not faced any regulatory criticism for non-compliance in information disclosure during the reporting period[129]. - The company’s governance structure aligns with legal and regulatory requirements, with no significant discrepancies identified[131]. - The company is committed to maintaining the interests of minority shareholders and ensuring compliance with corporate governance standards[160]. - The company has established a market value management system to protect investor rights and enhance investment value, approved by the board on January 22, 2025[121]. Environmental Responsibility - The company achieved a wastewater treatment capacity of 300m³/d after upgrading its wastewater system, ensuring compliance with national discharge standards[181]. - The company reported a 100% utilization rate for solid waste and a 100% legal disposal rate for hazardous waste during the reporting period[183]. - The company has not faced any environmental penalties or incidents during the reporting period[186]. - The company emphasizes effective measures to control pollution at all stages of production operations[199]. Employee Development and Corporate Culture - The company has established a comprehensive training system, conducting over 70 training sessions in 2024 with more than 1,730 participants[167]. - The company achieved a 100% health check rate for employees and reported a zero incidence rate of occupational diseases in 2024[191]. - The total number of employees at the end of the reporting period is 634, including 228 at the parent company and 406 at major subsidiaries[165]. - The professional composition includes 313 production personnel, 72 sales personnel, 102 technical personnel, 27 financial personnel, and 120 administrative personnel[165]. Strategic Direction and Future Plans - The company plans to focus on improving its operational management and market strategies in response to macroeconomic conditions[161]. - The company is exploring partnerships with international firms to leverage global market opportunities and enhance distribution channels[139]. - The company is currently in the process of evaluating its strategic direction and potential market expansions[138]. - In 2025, the company will focus on expanding its TCM segment while developing medical devices and chemical drugs, ensuring efficient completion of annual operational tasks[106].

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 甘肃陇神戎发药业股份有限公司（以下简称"公司"）控股子公司甘肃普安 制药股份有限公司（以下简称"普安制药"）于 2025 年 3 月 27 日收到国家药品 监督管理局核准签发的《药物临床试验批准通知书》，现将相关情况公告如下： 一、药物基本情况 药物名称：布瑞哌唑口溶膜 受理号：CXHL2500082 证券代码：300534 证券简称：陇神戎发 公告编号：2025-034 甘肃陇神戎发药业股份有限公司 关于控股子公司获得药物临床试验批准通知书的公告 通知书编号：2025LP00911 剂型：口溶膜剂 注册分类：化药 2 类改良型新药 申请事项：境内生产药品注册临床试验 规格：2mg/片 申请人：甘肃普安制药股份有限公司 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，2025 年 1 月 16 日受理的布瑞哌唑口溶膜符合药品注册的有关要求，同意开展精神分 裂症的临床试验。 二、对公司的影响及风险提示 布瑞哌唑口溶膜可用于精神分裂症的治疗。本次获得该药物的临床试验批准， 标志着普安制药开发的布瑞哌唑口 ...

Core Insights - BYD reported a net profit of 40.254 billion yuan for 2024, representing a 34% year-on-year increase, with R&D investment reaching 54.2 billion yuan [1][2] - Guangzhou Development plans to invest 5.612 billion yuan in the construction of the Guangzhou Pearl River Power Plant, a 2×600MW coal power environmental replacement project [1][2] - Cloud Tianhua's net profit for 2024 is 5.333 billion yuan, a year-on-year growth of 17.93%, with a proposed dividend of 1.4 yuan per share [1][2] Company Announcements - Ocean King currently has no business or products related to "deep-sea technology" [1] - Youfu Co., Ltd. reported that sales revenue from seawater polyester industrial yarn accounts for approximately 1% of the company's total revenue, indicating a low proportion [1] - Yida Co., Ltd. achieved production and sales of epoxy propylene products but did not achieve profitability [1] Project Investments - Chuangwei Digital plans to invest no more than 932 million yuan in the second phase of the Huizhou Industrial Park project [2] - Oriental Electric plans to establish a subsidiary and build a production base in Thailand [2] Contract Awards - Yonggui Electric's subsidiary won a project worth 23.218 million yuan [2] - Jinpu Garden signed a construction project general contracting contract worth approximately 215 million yuan [2] - Huaxi Energy signed a contract for a 1,800MW clean energy project in southern Laos, with a corresponding contract amount of 10.385 billion yuan [2] Share Buybacks and Transfers - Jian Sheng Group plans to repurchase shares with an investment of 50 to 100 million yuan [3] - Longshen Rongfa intends to purchase 70% equity of a research institute for 8.58494 million yuan [3] Other Developments - Rui Ge Mould plans to issue convertible bonds to raise no more than 880 million yuan for investment in intelligent manufacturing projects for new energy vehicles [1][3] - Yiwei Lithium Energy's subsidiary received a supplier designation notification from Changan Automobile [1][3]

重大科研布局！陇神戎发收购药投创新研究院70% 股权 助力产业升级 3月24日盘后，陇神戎发（300534）发布公告，拟以自有资金858.494万元收购控股股东甘肃药业集 团持有的甘肃药业集团科技创新研究院有限公司(以下简称"创新研究院")70%股权。交易完成后，创新 研究院将成为公司持股70%的控股子公司，纳入合并报表范围。本次收购有助于完善公司在科研平台建 设、检验检测服务领域的战略布局，增强综合科研实力与市场竞争力，标志着公司在中医药全产业链创 新领域迈出关键一步，进一步加强专业化科研平台建设，并推动科研成果加速转化与产业协同发展。 根据公开信息，创新研究院成立于2020年7月，是具有现代企业与科研平台双重优势的"新型研发机 构"，聚焦科技创新、检验检测、成果转化三大主线，核心技术覆盖药品研发、中药材安全性评价及药 品质量提升等领域。创新研究院前期聘请中国工程院院士庞国芳为首席科学家，牵头组建甘肃省中医药 产业创新联合体，联合产业链上下游50家单位，依托甘肃特色中药材资源优势，开展甘肃省中医药产业 重大共性技术研究，已获批立项6个重大专项，涵盖中医药全产业链子课题19项；已申请专利12项，软 件著作1个 ...

证券代码：300534 证券简称：陇神戎发 公告编号：2025-022 甘肃陇神戎发药业股份有限公司 第五届监事会第八次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 甘肃陇神戎发药业股份有限公司（以下简称"公司"）第五届监事会第八次 会议于 2025 年 3 月 21 日在公司六楼会议室现场召开，会议通知于 2025 年 3 月 18 日通过电子邮件等方式通知全体监事。本次会议由公司监事会主席邓育阳先 生主持，应出席会议监事 4 人，实际出席会议监事 4 人。本次会议的召集、召开 符合《公司法》等有关法律、行政法规、部门规章和《公司章程》的相关规定， 合法有效。 的资产评估报告为定价基础，交易定价合理、公允。本次交易不会对公司的财务 状况和经营成果产生不利影响，长期将对公司整体科研实力提升和经营发展产生 积极影响，符合公司发展战略和全体股东的利益。 本议案具体内容详见公司同日在巨潮资讯网（www.cninfo.com.cn）披露的 《关于现金收购甘肃药业集团科技创新研究院有限公司70%股权暨关联交易的公 告》。 表决结果 ...

证券代码：300534 证券简称：陇神戎发 公告编号：2025-021 甘肃陇神戎发药业股份有限公司 第五届董事会第十六次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 表决结果：同意 6 票，反对 0 票，弃权 0 票。关联董事宋月红女士、付瑞先 生对本议案回避表决。 三、备查文件 1.公司第五届董事会第十六次会议决议； 甘肃陇神戎发药业股份有限公司（以下简称"公司"）第五届董事会第十六 次会议通知于 2025 年 3 月 18 日以电子邮件方式等方式发出，会议于 2025 年 3 月 21 日在公司六楼会议室现场召开。本次会议由公司董事长康永红先生主持， 应出席会议董事 8 人，实际出席会议董事 8 人，公司监事、高级管理人员列席了 会议。本次会议的召集、召开符合《公司法》等有关法律、行政法规、部门规章 和《公司章程》的相关规定，合法有效。 二、董事会会议审议情况 会议审议并通过了如下议案： 1.审议通过《关于现金收购甘肃药业集团科技创新研究院有限公司 70%股权 暨关联交易的议案》 为完善公司在科研平台建设、检验检测 ...

| 报告编码: | 4747020050202500554 | | | --- | --- | --- | | 合同编号: | PXAL-B/SS2025-GGS0040 | | | 报告类型: | 法定评估业务资产评估报告 | | | 报告文号: | 鹏信资评报字 2025 第S039号 | | | 报告名称: | 甘肃陇神戎发药业股份有限公司拟收购甘肃药业集团科技创新研 究院有限公司部分股权所涉及的甘肃药业集团科技创新研究院有 | | | | 限公司股东全部权益市场价值资产评估报告 | | | 评估结论: | 12,264,240.17元 | | | 评估报告日: | 2025年02月22日 | | | 评估机构名称: | 深圳市鹏信资产评估土地房地产估价有限公司 | | | 签名人员: | 姚建军 (资产评估师) 正式会员 编号:62090005 | | | | 符言波 (资产评估师) 正式会员 编号:62140001 | | | | | 姚建军、符嵩波已实名认可 | | | | = Valle = | 本资产评估报告依据中国资产评估准则编制 甘肃陇神戎发药业股份有限公司拟收购 甘肃药业集团科技创新研究 ...

甘肃药业集团科技创新研究院有限公司 审 计 报 告 希会审字（2025）0225 号 目 录 一、审计报告 ……………………………… （1-3） 二、财务报表 （一）合并财务报表 1.合并资产负债表………………………（4-5） 2.合并利润表 ………………………… （6） 3.合并现金流量表 ………………………（7） 4.合并所有者权益变动表………………（8-9） （二）母公司财务报表 1.母公司资产负债表…………………（10-11） 2.母公司利润表 …………………………（12） 3.母公司现金流量表 ……………………（13） 4.母公司所有者权益变动表…………（14-15） 三、财务报表附注 …………………………（16-82） 四、证书复印件 （一）注册会计师资质证明 （二）会计师事务所营业执照 （三）会计师事务所执业证书 希格玛会计师事务所(特殊普通合伙) Xigema Cpas(Special General Partnership) 希会审字(2025)0225 号 审计报告 甘肃药业集团科技创新研究院有限公司: 一、审计意见 我们审计了甘肃药业集团科技创新研究院有限公司(以下简称贵公司)财务报 表 ...